HUGHES, PATRICK M.,BURKE, JAMES A.,CHANG-LIN, JOAN-EN
申请号：
CA2603069
公开号：
CA2603069C
申请日:
2006.05.09
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
Ophthalmically therapeutic materials, such as liquid-containing compositionsand polymeric drug delivery systems, include a therapeutic component whichincludes an alpha 2 adrenergic receptor agonist that is cleared from theanterior segment of an individual's eye to which the material is administered.The alpha 2 adrenergic receptor agonist may have a vitreal half-life greaterthan about three hours. The present materials are effective in treating anocular condition(s) that affect the anterior segment of an eye, or theanterior and posterior segment of the eye. The materials are suitable forintravitreal or periocular administration and can provide prolonged drugdelivery and therapeutic benefits to patients to which the materials have beenadministered. The alpha 2 adrenergic receptor agonists can be provided inliquid-containing formulations and/or bioerodible and/or non-bioerodiblepolymeric implants and microparticles. Methods of making and using the presentmaterials are also described.
